ArticleEmerging infectious diseases2026
National Surveillance of Enterovirus D68 Upsurge, France, 2024.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2024, an early and rapid rise in enterovirus D68 (EV-D68) infections in France prompted the implementation of enhanced nationwide surveillance to characterize the outbreak. EV-D68 screening was performed as part of the routine hospital strategy of the 2 national reference laboratories and of the national surveillance of enterovirus infections. Of 919 patients, 49.1% (451/919) were adults. Severe infection was reported in 169 patients (102 children and 67 adults). We observed neurologic complications in 7 children (seizures and encephalitis) and 4 adults (myelitis). Infections peaked in week 38 and were associated with subgenotypes A2 and B3; A2 predominated, particularly in adults (317/457 [69.3%] A2 infections). Complete genome analyses identified a new A2-derived lineage with mutations clustering in exposed regions of viral capsid protein 1. Our findings highlight the substantial clinical impact of EV-D68 in adults as well as children, underscoring the need for broad clinical and genomic surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.